Founded and headquartered in Dallas, Texas, in 2010, we've grown our capabilities to conduct our registration-enabling clinical studies in the United States, Europe, and China. Our enrolling Phase 3 clinical programs are carefully and purposefully designed to provide clear transformational cancer treatments against validated targets where only incremental advances have been made over chemotherapy in the last 20 years.
Data Driven - To date, AROG has evaluated crenolanib in over 15 completed and ongoing clinical trials in over 500 patients. Experience Oriented- We have assembled an experienced and talented group of leaders to execute our vision. Since then, we have discovered the FLT3 mechanism of action and have launched two Phase III clinical trials in FLT3 mutant AML.
Data Driven - To date, AROG has evaluated crenolanib in over 15 completed and ongoing clinical trials in over 500 patients. Experience Oriented- We have assembled an experienced and talented group of leaders to execute our vision. Since then, we have discovered the FLT3 mechanism of action and have launched two Phase III clinical trials in FLT3 mutant AML.
Services
Arog Pharmaceuticals is a Phase 3 biopharmaceutical company dedicated to developing our lead investigational drug candidate, crenolanib, and a related class of benzimidazole-based compounds to become treatment options for cancer indications with high unmet medical need. We founded Arog in 2010 after securing exclusive global rights to our product candidates from Pfizer.
Crenolanib is a small molecule investigational drug candidate that is being evaluated for safety and efficacy in Phase 3 clinical trials in acute myeloid leukemia (AML) and gastrointestinal stromal tumor (GIST). Crenolanib is a potent small molecule inhibitor of wild-type and mutant forms of FLT3 (FMS-like Tyrosine Kinase 3) and PDGFR/ (Platelet-Derived Growth Factor Receptor).
This is our company-sponsored, Phase III clinical trial of crenolanib in combination with salvage chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) with mutations in the FLT3 gene. This study aims to find out how safe and effective this treatment is, compared with placebo, in this type of cancer.
Glioma is a common type of tumor originating in the brain. About 33 percent of all brain tumors are gliomas, which originate in the glial cells that surround and support neurons in the brain, including astrocytes, oligodendrocytes and ependymal cells. Glioblastomas (also called GBM) are the most invasive type of glial tumors and represent about 15% of all primary brain tumors.
The request must be submitted to Arog by the treating physician, with contact information so it can be followed up. Patients with underlying conditions that may pose safety risks would not be eligible to participate. Exhausted all available therapies and is no longer responsive or able to tolerate these therapies.
Reviews
Be the first to review Arog Pharmaceuticals.
Write a Review
